Omnicell stock: buy or sell?
July 16th, 2019
Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide.
Should I buy Omnicell stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best time to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Omnicell stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Omnicell stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we gathered 2 ratings published for OMCL stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-3-7||Dougherty & Co||n/a||Buy|
|2019-2-8||Piper Jaffray Companies||n/a||Neutral|
Omnicell stock analysis
After boosting an exceptional 7.57% yesterday, Omnicell closed today at $71.19 and plunged a chilling -4.10%.
After boosting an exceptional 7.57% yesterday, Omnicell closed today at $71.19 and plunged a chilling -4.10%. Since last March when SMA50d and SMA100d crossed up, OMCL price slipped $-13.76 per share (-16.20%). On Jun 21st, OMCL hit a new all time high, pushing higher than on June/20 tops. Check different trading setups that use ATHs as triggers.
After sliding a frightening -25.75% in a week last week, Omnicell closed this week at $71.19 and jumped a very good 3.76%. By mid June OMCL rocketed an outstanding 12.12% in just one week.
Not so far away is the last price record Omnicell marked by mid June, but since then it dropped a 23.11%. Since last week, when OMCL stock price broke down the 40-weeks moving avarage line, it slid $-15.09 per share (-17.49%). Stocks below the 40w moving average line are usually not recommended for average traders.
Omnicell stock price history
Omnicell IPO was on August 9th, 2001 at $8.71 per share1. Since then, OMCL stock surged a 717.30%, with a yearly average of 42.20%. If you had invested right after OMCL's IPO a $1,000 in Omnicell stock in 2001, it would worth $7,173.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Omnicell stock historical price chart
OMCL stock reached all-time highs on Jun/21 with a price of $92.59.
Omnicell stock price target is $80.00Nobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. We detected 2 price forecasts for OMCL stock published in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-3-7||Dougherty & Co||Raises Target||$78.00||$90.00||15.4%|
|2019-2-8||Piper Jaffray Companies||Reiterates||n/a||$70.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter presenting its last earnings report on April, Omnicell slipped an awful -8.08%. As soon as we get its actual EPS from the earnings report, we will update this report.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw a brilliant growth of 10.47% to $787.31 M dollars. Instead, its income margin (compared to sales) remained constant to 4.79%, that is $37.73 million. To have an up to date view of the financial situation of Omnicell, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2019-Q1 that can be compared to 2018 fiscal year results. Annual Omnicell TTM sales up to March 2019 were $807.21 and income was $38.29 M USD. If we compare this TTM figures with the last reported annuality, we can esteem Omnicell business evolution since December 2018: Annual revenues up to March, compared to lastest yearly report, gained a slightly good 2.53%. However, profit margin (net income/revenues) remained constant at 4.79%.
|2013||$381 M||-||$24 M6.3%||-|
|2014||$441 M||15.85%||$31 M6.9%||27.26%|
|2015||$485 M||9.90%||$31 M6.3%||0.79%|
|2016||$693 M||42.94%||$0.60 M0.1%||-98.04%|
|2017||$713 M||2.90%||$31 M4.3%||4,961.03%|
|2018||$787 M||10.47%||$38 M4.8%||23.63%|
|TTM||$807 M||2.53%||$38 M4.7%||1.49%|
Quarterly financial resultsOmnicell posted $202.52 M in sales for 2019-Q1, a -4.36% decline compared to previous quarter. Reported quarter income marked $3.28 M with a profit margin of 1.62%. Profit margin eased a -5.36% compared to previous quarter when profit margin was 6.99%. When comparing turnover to same quarter last year, Omnicell sales marked a cool gain and climbed a 10.90%.
|2017-Q2||$181 M||-||$1 M0.5%||-|
|2017-Q3||$187 M||3.26%||$6 M3.3%||644.32%|
|2017-Q4||$200 M||6.98%||$21 M10.7%||242.09%|
|2018-Q1||$183 M||-8.61%||$3 M1.5%||-87.24%|
|2018-Q2||$189 M||3.32%||$7 M3.5%||142.21%|
|2018-Q3||$204 M||8.27%||$14 M6.7%||106.86%|
|2018-Q4||$212 M||3.66%||$15 M7.0%||8.55%|
|2019-Q1||$203 M||-4.36%||$3 M1.6%||-77.80%|
Omnicell ownershipWhen you are planning to buy a company, it's worth to overview its ownership structure.
Omnicell shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 2.06% of all shares.
Bearish positions for OMCL stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Omnicell:
|Market cap||$2.9 B||$18.9 B||$13.9 B||$24.2 B||$160.0 M|
|Total shares||41.2 M||210.2 M||298.1 M||325.4 M||33.8 M|
|Float shares||40.3 M||152.8 M||297.1 M||314.3 M||32.9 M|
|- Institutional holdings (%)||96.5%||68.0%||92.4%||82.8%||124.2%|
|- Insider holdings (%)||2.1%||27.1%||0.3%||4.4%||3.5%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Tuesday, July 16th, 2019|
|Day range||$70.52 - $74.04|
|Average true range||$4.10|
|50d mov avg||$82.33|
|100d mov avg||$81.77|
|200d mov avg||$74.94|
Omnicell performanceTo measure stock performance is always good to compare with competitors or related stocks. In the following table, we compare Omnicell performance to , Cardinal Health, Cerner, Invacare, McKesson and Premier: